CN107743494B - 具有极性重组延伸体的胰岛素 - Google Patents

具有极性重组延伸体的胰岛素 Download PDF

Info

Publication number
CN107743494B
CN107743494B CN201680031703.8A CN201680031703A CN107743494B CN 107743494 B CN107743494 B CN 107743494B CN 201680031703 A CN201680031703 A CN 201680031703A CN 107743494 B CN107743494 B CN 107743494B
Authority
CN
China
Prior art keywords
gly
pro
gln
glu
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680031703.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107743494A (zh
Inventor
T.B.克杰德森
T.霍伊格-詹森
T.N.温特
F.胡巴雷克
I.佩特斯森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN107743494A publication Critical patent/CN107743494A/zh
Application granted granted Critical
Publication of CN107743494B publication Critical patent/CN107743494B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201680031703.8A 2015-06-02 2016-06-02 具有极性重组延伸体的胰岛素 Expired - Fee Related CN107743494B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15170337 2015-06-02
EP15170337.8 2015-06-02
EP15176207.7 2015-07-10
EP15176207 2015-07-10
PCT/EP2016/062514 WO2016193380A1 (en) 2015-06-02 2016-06-02 Insulins with polar recombinant extensions

Publications (2)

Publication Number Publication Date
CN107743494A CN107743494A (zh) 2018-02-27
CN107743494B true CN107743494B (zh) 2022-04-29

Family

ID=56098249

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680031703.8A Expired - Fee Related CN107743494B (zh) 2015-06-02 2016-06-02 具有极性重组延伸体的胰岛素

Country Status (6)

Country Link
US (1) US11208452B2 (https=)
EP (1) EP3303380B1 (https=)
JP (2) JP6983075B2 (https=)
CN (1) CN107743494B (https=)
ES (1) ES2784603T3 (https=)
WO (1) WO2016193380A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー/エス 極性の組換え延長部を有するインスリン
CN108136043B (zh) 2015-10-01 2022-09-06 诺和诺德股份有限公司 蛋白质缀合物
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
CN110505885A (zh) * 2017-04-05 2019-11-26 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物
JP7589049B2 (ja) * 2018-06-21 2024-11-25 ノヴォ ノルディスク アー/エス 肥満を治療するための新規化合物
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
CN112839681A (zh) 2018-10-10 2021-05-25 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物及其医学用途
FI4073098T3 (fi) 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN115260313B (zh) * 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN116096733A (zh) 2020-04-10 2023-05-09 阿卡斯通生物科学公司 Covid-19融合蛋白的抗原特异性免疫疗法和使用方法
DE102020110543A1 (de) 2020-04-17 2021-10-21 Bayerische Motoren Werke Aktiengesellschaft Energiespeichereinrichtung, Kraftfahrzeug und Kühlplattenanordnung
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP3915571A1 (en) * 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
CN114729060B (zh) * 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN115716877B (zh) * 2022-07-04 2023-09-01 北京惠之衡生物科技有限公司 一种表达glp-1和胰岛素缀合物多肽的重组工程菌
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111516A (zh) * 2005-01-25 2008-01-23 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
CN101528773A (zh) * 2006-10-27 2009-09-09 诺沃-诺迪斯克有限公司 氨基酸延长的胰岛素
CN102666586A (zh) * 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
CN103172747A (zh) * 2005-01-25 2013-06-26 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE257197C (https=)
DE286509C (https=)
US3914252A (en) 1971-03-15 1975-10-21 Continental Oil Co Preparation of N-iodocompounds
DD257197A1 (de) 1987-01-28 1988-06-08 Univ Dresden Tech Verfahren zur herstellung von immobilisierten, in ihrer biologischen aktivitaet stabilisierten und in ihren pharmakologischen eigenschaften modifizierten insulinpraeparationen
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DD286509A5 (de) 1989-06-30 1991-01-31 Veb Berlin-Chemie,De Verfahren zur herstellung von aktivitaetsstabilisierten, wirkungsverlaengerten rektal applizierbaren insulinpraeparationen
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
CA2230492C (en) 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
WO1998022577A1 (en) 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
EP0946735B1 (en) 1996-12-20 2006-02-08 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1352062A2 (en) 2001-01-11 2003-10-15 Maxygen Aps Improved growth hormone molecules
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
PE20020908A1 (es) 2001-03-21 2002-10-26 Cell Therapeutics Inc Produccion recombinante de polimeros polianionicos y uso de de los mismos
US20050233417A1 (en) 2001-11-12 2005-10-20 Cooper David N Growth hormone variations in humans and their uses
GB2389115B (en) 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1843790A2 (en) 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
BRPI0607775A2 (en) 2005-02-16 2018-06-26 Novo Nordisk A/S conjugate, pharmaceutical composition, use of a compound, and method for treating or preventing disease
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2006324488B2 (en) 2005-12-12 2013-03-21 Abcam Limited Production of conjugates
CN101384272B (zh) 2005-12-20 2013-05-01 杜克大学 用于递送具有增强的药理性质的活性剂的方法和组合物
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
JP5256199B2 (ja) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド アルブミン−インスリン融合タンパク質
PT2094728E (pt) 2006-10-26 2013-05-27 Janssen Biotech Inc Métodos de adaptação de anticorpos monoclonais ao ser humano
WO2008147456A2 (en) 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
KR20080095141A (ko) 2007-04-23 2008-10-28 포항공과대학교 산학협력단 인간 알부민 링커를 통하여 면역글로불린의 Fc에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
CN105131127B (zh) 2007-05-30 2018-09-07 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
JP5314033B2 (ja) 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異IgGFcフラグメントと融合した単一IFN−ベータ
KR101784231B1 (ko) 2008-06-20 2017-11-08 노파르티스 아게 응집이 감소된 면역글로불린
US20110119848A1 (en) 2008-07-02 2011-05-26 Koninklijke Philips Electronics N.V. V-spring configuration and end attachment assemblies therefor for use in a personal care appliance
UA101670C2 (ru) 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца
CA2748314C (en) * 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
US20120276092A1 (en) 2009-10-29 2012-11-01 Jinquan Luo Antibody Glycosylation Variants
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
WO2011144756A1 (en) 2010-05-21 2011-11-24 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US9783571B2 (en) 2011-04-05 2017-10-10 Warham Lance Martin Isolation of cysteine containing peptides
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
CA2873112A1 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー/エス 成熟インスリンポリペプチドを作製するための方法
CN105792851B (zh) 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
JP6620094B2 (ja) 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 免疫応答を調節するための組成物および方法
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Fc蛋白質
CN106687482B (zh) 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
US10894089B2 (en) 2015-02-17 2021-01-19 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue conjugate
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー/エス 極性の組換え延長部を有するインスリン
CA2994853C (en) 2015-08-14 2023-06-27 Rc Biotechnologies, Inc. Covalent linkers in antibody-drug conjugates and methods of making and using the same
CN108136043B (zh) 2015-10-01 2022-09-06 诺和诺德股份有限公司 蛋白质缀合物
CN110505885A (zh) 2017-04-05 2019-11-26 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111516A (zh) * 2005-01-25 2008-01-23 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
CN103172747A (zh) * 2005-01-25 2013-06-26 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
CN101528773A (zh) * 2006-10-27 2009-09-09 诺沃-诺迪斯克有限公司 氨基酸延长的胰岛素
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
CN102666586A (zh) * 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer;Vladimir N.Podust et al.;《Protein Engineering, Design & Selection》;20131016;第26卷(第11期);第743-753页 *

Also Published As

Publication number Publication date
JP2018527288A (ja) 2018-09-20
JP2021119156A (ja) 2021-08-12
US20180291076A1 (en) 2018-10-11
US11208452B2 (en) 2021-12-28
EP3303380B1 (en) 2020-01-15
ES2784603T3 (es) 2020-09-29
CN107743494A (zh) 2018-02-27
EP3303380A1 (en) 2018-04-11
WO2016193380A1 (en) 2016-12-08
JP6983075B2 (ja) 2021-12-17

Similar Documents

Publication Publication Date Title
CN107743494B (zh) 具有极性重组延伸体的胰岛素
TWI686403B (zh) 新穎胰島素衍生物及其醫療用途
JP2021177779A (ja) 新規インスリン誘導体及びその医学的使用
MXPA02001139A (es) Polipeptidos quimericos, metodos para su produccion y usos de los mismos.
WO2013188181A1 (en) Fibroblast growth factor 21 proteins
EP1991575A1 (en) Single-chain insulin analogues and pharmaceutical formulations thereof
JPH11502110A (ja) インスリン誘導体
US20200283493A1 (en) Novel Insulin Derivatives and the Medical Uses Hereof
KR102427426B1 (ko) 신규한 인슐린 유사체 및 이의 용도
JP2018531899A (ja) 新規インスリン誘導体及びその医学的使用
CN115960246B (zh) 一种重组环状人生长激素-Fc融合蛋白及其应用
JP2006508695A (ja) 単量体インスリン

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220429

CF01 Termination of patent right due to non-payment of annual fee